page contents
Photo by Dzenina Lukac on Pexels.com

FDA Approves Marketing of Woman’s Menopausal Status PicoAMH Test

PicoAMH Elisa Women Menopausal Status Test Cleared By FDA to Be Sold Commercially

(FDA Release)

Today, the U.S. Food and Drug Administration permitted marketing of the PicoAMH Elisa diagnostic test as an aid in the determination of a patient’s menopausal status.

“Diagnostic results about a woman’s menopausal status may prompt discussions about preventative care for women experiencing menopausal symptoms,” said Courtney Lias, Ph.D. director of the Division of Chemistry and Toxicology Devices in the FDA’s Center for Devices and Radiological Health. “This test, when used in conjunction with other clinical assessments and laboratory findings, can help inform discussions about preventative care, such as ways to help prevent loss in bone mineral density or to address cardiovascular disease, both of which are known to increase after menopause.”

Menopause refers to the time in a woman’s life when she stops having a menstrual period and is no longer fertile. During the menopausal transition, the body's production of estrogen and progesterone, two hormones made by the ovaries, varies greatly. Bones become less dense, making women more vulnerable to fractures. During this period, lipid profiles may change including increases in low density lipoprotein (LDL), a type of cholesterol. After menopause, women enter post-menopause, when they are more vulnerable to heart disease and osteoporosis. It is important for women to understand their stage of menopausal transition to learn what, if any, additional health risks they may face and any preventative health steps to take.

The PicoAMH Elisa test measures the amount of Anti-Müllerian Hormone (AMH) in the blood. AMH levels represent one indicator available to clinicians to determine whether a woman is approaching or is likely to have reached her final menstrual period. The PicoAMH Elisa test is meant to be used only in conjunction with other clinical assessments and laboratory findings.

The FDA reviewed data submitted by the sponsor that included 690 women, aged 42 to 62, who participated in the multi-center, longitudinal Study of Women’s Health Across the Nation . The data showed that the PicoAMH Elisa test performed reasonably well at determining levels of AMH in the blood and identifying women who had their last menstrual period and women who were more than five years away from their last menstrual period.

Clinicians should carefully evaluate PicoAMH Elisa test results in the context of a full clinical work up to ensure that contraceptives are not discontinued in women who have not yet reached menopause and that uterine bleeding due to endometrial cancer is not dismissed as a diagnosis. The PicoAMH Elisa test should not be used to assess a woman’s fertility status or to monitor or predict the ovarian response in women undergoing or planning to undergo fertility treatments.

The FDA reviewed data for the PicoAMH Elisa test through the de novo premarket review pathway, a regulatory pathway for low-to-moderate-risk devices of a new type. Along with this authorization, the FDA is establishing criteria, called special controls, which set forth the agency’s expectations in assuring the accuracy, clinical performance and labeling of tests intended to be used as an aid in the determination of a patient’s menopausal status. These special controls, when met along with general controls, provide a reasonable assurance of safety and effectiveness for these tests.

The FDA granted marketing authorization of the PicoAMH Elisa test to Ansh Labs.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

###

Check Also

The U.S. Economy Improved in October, Housing Starts and Building Permits Data Show

The U.S. economy continues to show signs of improvement. It has been the third week in a row that we have seen positive economic numbers. This week’s offering provides us with positive releases such as the Housing Starts, Building Permits, Existing Home Sales, Manufacturing PMI, Services PMI, and Consumer Sentiment Reports.

Recent Interest Rate Cuts, Already Showing Economic Improvements

When the economy begins to expand, the inflation rate will also begin to increase. Therefore, the Federal Reserve must be extremely careful when cutting interest rates because cutting interest rates too much could cause inflation to rise too quickly.

U.S. Economy Boosted by Improved Trade Deficit and ISM Non-Manufacturing PMI

The Trade Balance, released by the Bureau of Economic Analysis, measures the difference in value between imported and exported goods or services over the reported period. A positive number indicates that more goods and services were exported than imported. A Trade Balance with a negative value is called a trade deficit while a Trade Balance with a positive number is called a trade surplus. As we have mentioned previously a Trade Balance equals the value of exports minus the value of imports.

Recession Worries Caused Fed to Cut Interest Rate By 25 Basis Points to 1.75 Percent

Even consumers don’t feel all that confident about the economy. The recent Conference Board Consumer Confidence Report for October showed that consumers are less confident about the economy now, than they were a month earlier. The CB Consumer Confidence Report released Tuesday, October 29, 2019, at 10 AM, for October, posted current readings of 125.9 missing forecast of 128.0 and a previous reading of 126.3.

U.S. Economy Stares Recession in the Face, 25 Percent Interest Rate Cut Expected by Fed on Wednesday!

Based on the current New Homes Sales Report, the U.S. economy continues to show slow growth, signaling that the expansion phase, of the business cycle could be coming to an end. The economy began expanding from June 2009, right after the stock market crash of 2008, until now, 11 years later.

U.S. Economy Tip Toeing on Edge of Recession, Retail Sales and Housing Starts Data Show!

If this is not a recession, then I don’t know what is? Can the U.S. economy get any worse than this? Week after week, we continue to get negative economic growth numbers. The GDP hasn’t moved from 2% for the past few months. I know that the classification of a recession is 2 consecutive quarters of negative GDP growth and the classification of a Depression is 8 consecutive quarters of negative GDP growth, but come on!

US Economy Experiencing Slow Growth Confirmed by Non-farm Payroll, Manufacturing, and Retail Sales Data

The Core Retail Sales Report measures changes in the total value of sales at the retail level in the U.S., excluding automobiles. The report shows the rate of consumer spending. It functions as a pace indicator for the U.S. economy, how fast or how slow the growth of the economy is currently progressing. As we can see in the report, the previous reading was 1.0%, the forecasted reading 0.1%, and the actual reading came in at 0.0%. So, this is confirming that U.S. economic growth has slowed down dramatically or is slowly growing.

%d bloggers like this: